Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Oxford BioDynamics Plc (OBD.L)
Oxford, GB
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00% | -5.61% | -9.76% | -28.85% | -27.45% | -13.95% | -58.89% | -98.63% | -99.72% | -99.88% | -99.88% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+72.2% ★ Q1'26: +110.1% (vs Q1'24)
-
EPS growth Biotechnology: +29.7%+82.3% ★ Q1'26: +94.9% (vs Q1'24)
-
FCF margin FCF growth · Biotechnology: +16.2%-828.6% Q1'26: -657.9% (vs Q1'24)
-
EBIT margin Biotechnology: +0.0%-1,004.6% Q1'26: -686.3% (vs Q1'24)
-
ROIC Biotechnology: -16.1%-227.5% Q1'26: -366.3% (vs Q1'24)
-
Share dilution Biotechnology: -3.4%+442.4% Q1'26: +1,780.2% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.52× Q1'26: -0.26× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2016 actual |
Sep 2017 actual |
Sep 2018 actual |
Sep 2019 actual |
Sep 2020 actual |
Sep 2021 actual |
Sep 2022 actual |
Sep 2023 actual |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.09M
est: 1.00M (+9.1%)
|
1.18M
est: 1.19M (-0.6%)
|
1.19M
est: 1.00M (+18.6%)
|
907.0K
est: 1.19M (-23.8%)
|
456.0K
est: 1.24M (-63.3%)
|
341.0K
est: 1.20M (-71.6%)
|
154.0K
est: 2.12M (-92.7%)
|
510.0K
est: 5.79M (-91.2%)
|
636.0K
est: 630.0K (+1.0%)
|
1.10M
est: 1.45M (-24.6%)
|
1.80M
1.80M – 1.80M
+23.9% YoY
|
| EBITDA |
-1.91M
est: -1.00M (-90.8%)
|
-3.79M
est: -1.19M (-218.4%)
|
-2.09M
est: -1.00M (-109.2%)
|
-3.00M
est: -3.23M (+7.1%)
|
-4.42M
est: -6.23M (+28.9%)
|
-6.43M
est: -17.00M (+62.2%)
|
-6.16M
est: -43.09M (+85.7%)
|
-9.84M
est: -109.39M (+91.0%)
|
-10.27M
est: -630.0K (-1,529.4%)
|
-9.80M
est: -1.45M (-574.5%)
|
-1.80M
-1.80M – -1.80M
-23.9% YoY
|
| EBIT |
-2.07M
est: -1.00M (-107.4%)
|
-4.03M
est: -1.19M (-238.7%)
|
-2.42M
est: -1.00M (-142.3%)
|
-3.39M
est: -3.38M (-0.1%)
|
-4.89M
est: -8.71M (+43.8%)
|
-7.52M
est: -23.77M (+68.4%)
|
-7.37M
est: -60.26M (+87.8%)
|
-11.20M
est: -152.98M (+92.7%)
|
-11.73M
est: -630.0K (-1,762.1%)
|
-11.00M
est: -1.45M (-657.1%)
|
-1.80M
-1.80M – -1.80M
-23.9% YoY
|
| Net Income |
-1.73M
est: -6.39M (+72.9%)
|
-3.80M
est: -7.42M (+48.7%)
|
-1.95M
est: -6.39M (+69.5%)
|
-2.80M
est: -3.22M (+12.9%)
|
-4.31M
est: -6.55M (+34.1%)
|
-6.68M
est: -17.88M (+62.6%)
|
-6.71M
est: -45.32M (+85.2%)
|
-10.83M
est: -115.06M (+90.6%)
|
-11.57M
est: -61.03M (+81.0%)
|
-11.15M
est: -13.87M (+19.6%)
|
-3.11M
-3.11M – -3.11M
+77.6% YoY
|
| SGA |
903.0K
est: 7.59M (-88.1%)
|
1.35M
est: 9.04M (-85.1%)
|
1.08M
est: 7.59M (-85.7%)
|
1.42M
est: 9.04M (-84.3%)
|
1.32M
est: 9.43M (-86.0%)
|
1.85M
est: 9.11M (-79.7%)
|
2.45M
est: 16.11M (-84.8%)
|
3.41M
est: 43.99M (-92.2%)
|
4.48M
est: 4.87M (-8.0%)
|
3.90M
est: 11.23M (-65.3%)
|
13.91M
13.91M – 13.91M
+23.9% YoY
|
| EPS |
-0.02
est: -0.03 (+15.2%)
|
-0.04
est: -0.03 (-53.8%)
|
-0.02
est: -0.03 (+10.8%)
|
-0.03
est: -0.03 (-4.5%)
|
-0.05
est: -0.03 (-72.6%)
|
-0.07
est: -0.04 (-106.3%)
|
-0.07
est: -0.03 (-169.2%)
|
-0.07
est: 0.01 (-1,568.0%)
|
-0.05
est: -0.04 (-2.7%)
|
-0.01
est: -0.01 (+20.0%)
|
0.00
0.00 – 0.00
+77.6% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-19 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-01 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Iain Gladstone Ross | Executive Chairman | 286.5K | male |
| Alexandre Akoulitchev Ma | Chief Scientific Officer & Executive Director | 244.0K | — |
| Paul Leslie Stockdale | Chief Financial Officer & Executive Director | 211.0K | male |
| David Blum | Senior Vice President of Marketing | — | — |
| Ewan Hunter | Chief Data Officer | — | — |
| T. Demain | Company Secretary | — | — |
| Thomas G. Guiel | Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for OBD.L
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
